Amarin Halted Ahead of FDA Advisory Committee to Review sNDA for Vascepa( ANCHOR Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that NASDAQ has halted trading of the company's shares.
The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) is meeting today to openly discuss the company's supplemental New Drug Application (sNDA) for the proposed ANCHOR indication for Vascepa® (icosapent ethyl) and Amarin will hold a conference call at 7:00 pm Eastern time tonight to discuss the meeting (details previously announced).
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
Availability of other information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website